The detailed mechanisms determining the course of congestive heart failure (CHF) and associated renal dysfunction remain unclear. In a volume overload model of CHF induced by creation of aorto-caval fistula (ACF) in Hannover Sprague-Dawley (HanSD) rats we explored the putative pathogenetic contribution of epoxyeicosatrienoic acids (EETs), active products of CYP-450 dependent epoxygenase pathway of arachidonic acid metabolism, and compared it with the role of the renin-angiotensin system (RAS). Chronic treatment with cis-4-[4-(3-adamantan-1-yl-ureido) cyclohexyloxy]benzoic acid (c-AUCB, 3 mg/l in drinking water), an inhibitor of soluble epoxide hydrolase (sEH) which normally degrades EETs, increased intrarenal and myocardial EETs to levels observed in sham-operated HanSD rats, but did not improve the survival or renal function impairment. In contrast, chronic angiotensin-converting enzyme inhibition (ACEi, trandolapril, 6 mg/l in drinking water) increased renal blood flow, fractional sodium excretion and markedly improved survival, without affecting left ventricular structure and performance. Hence, renal dysfunction rather than cardiac remodeling determines long-term mortality in advanced stage of CHF due to volume overload. Strong protective actions of ACEi were associated with suppression of the vasoconstrictor/sodium retaining axis and activation of vasodilatory/natriuretic axis of the renin-angiotensin system in the circulating blood and kidney tissue.

Department of Pathophysiology 2nd Faculty of Medicine Charles University Prague Czech Republic

See more in PubMed

ABASSI Z, GOLTSMNA I, KARRAM T, WINAVER J, HOFFMAN A. Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy. J Biomed Biotechnol. 2011:729497. http://dx.doi.org/10.1155/2011/729497. PubMed DOI PMC

AI D, FU Y, GUO D, TANAKA H, WANG N, TANG C, HAMMOCK BD, SHYY JY, ZHU Y. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA. 2007;104:9018–9023. PubMed PMC

BENES J, KAZDOVA L, DRAHOTA Z, HOUSTEK J, MEDRIKOVA D, KOPECKY J, KOVAROVA N, VRBACKY M, SEDMERA D, STRNAD H, KOLAR M, PETRAK J, BENADA O, SKAROUPKOVA P, CERVENKA L, MELENOVSKY V. Effect of metformin therapy on cardiac function and survival in a volume-overload model of heart failure in rats. Clin Sci. 2011;129:29–41. PubMed

BENES J, Jr., MELENOVSKY V, SKAROUPKOVA P, POSPISILOVA J, PETRAK J, CERVENKA L, SEDMERA D. Myocardial morphological characteristics and proarrhytmic substrate in the rat model of heart failure due to chronic volume overload. Anat Rec. 2011;294:102–111. PubMed

BRAAM B, JOLES JA, DANISHWAR AH, GAILLARD CA. Cardiorenal syndrome – current understanding and future perspectives. Nat Rev Nephrol. 2014;10:48–55. PubMed

BROWER GL, HENEGAR JR, JANICKI JS. Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload. Am J Physiol. 1996;40:H2071–H2078. PubMed

BURGELOVÁ M, VAŇOURKOVÁ Z, THUMOVÁ M, DVOŘÁK P, OPOČENSKÝ M, KRAMER HJ, ŽELÍZKO M, MALÝ J, BADER M, ČERVENKA L. Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension. J Hypertens. 2009;27:1988–2000. PubMed

COHEN-SEGEV R, FRANCIS B, ABU-SALEH N, AWAD H, LAZAROVICH A, KABALA A, ARONSON D, ABASSI Z. Cardiac and renal distribution of ACE and ACE-2 in rats with heart failure. Acta Histiochem. 2014;116:1342–1349. PubMed

ČERVENKA L, BÍBOVÁ J, HUSKOVÁ Z, VAŇOURKOVÁ Z, KRAMER HJ, HERGET J, JÍCHOVÁ Š , SADOWSKI J, HAMPL V. Combined suppression of the intrarenal and circulating vasoconstrictor renin-ACE-ANG II axis and augmentation of the vasodilator ACE2-ANG 1-7-Mas axis attenuates the systemic hypertension in Ren-2 transgenic rats exposed to chronic hypoxia. Physiol Res. in press. PubMed

DICKSTEIN K, COHEN-SOLAL A, FILIPPATOS G, McMURRAY JJ, PONIKOWSKI P, POOLE-WILSON PA, STROMBERG A, van VELDHUISEN DJ, ATAR D, HOES AW, KEREN A, MEBAZAA A, NIEMINEN M, PRIORI SG, SWEDBERG K. Committee for practice guideline (GPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur J Heart Fail. 2008;10:933–989. PubMed

ELMARAKBY AA. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease. Am J Physiol. 2012;302:R321–R330. PubMed

GARCIA R, DIEBOLD S. Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res. 1990;24:430–432. PubMed

GIAMOUZIS G, KALEGEROPOULOS AP, BUTLER J, KARAYANNNIS G, GEORGIPOULOU VV, SKOULARIGIS J, TRIPOSKIADIS F. Epidemiology and importance of renal dysfunction in heart failure patients. Curr Heart Fail Rep. 2013;10:411–420. PubMed

HONETSCHLAGEROVÁ Z, SPORKOVÁ A, KOPKAN L, HUSKOVÁ Z, HWANG SH, HAMMOCK BD, IMIG JD, KRAMER HJ, KUJAL P, VERNEROVÁ Z, ČERTÍKOVÁ CHÁBOVÁ V, TESAŘ V, ČERVENKA L. Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2011;29:1590–1601. PubMed PMC

HUSKOVÁ Z, VAŇOURKOVÁ Z, ERBANOVÁ M, THUMOVÁ M, OPOČENSKÝ M, MULLINS JJ, KRAMER HJ, BURGELOVÁ M, ČERVENKA L. Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2010;28:495–509. PubMed

HUTCHINSON KR, GUGGILAM A, CISMOWSKI MJ, GALANTOWICS ML, WEST TA, STEWART JA, Jr., ZHANG X, LORD KC, LUCCHESI PA. Temporal pattern of left ventricular structural and functional remodeling following reversal of volume overload heart failure. J Appl Physiol. 2011;111:1778–1788. PubMed PMC

HWANG SH, TSAI HJ, LIU JY, MORISSEAU C, HAMMOCK BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007;50:3825–3840. PubMed PMC

ICHIKAWA I, PFEFFER JM, FEFFER MA, HOSTETTER TH, BRENNER BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res. 1984;55:669–675. PubMed

IMIG JD. Epoxide and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev. 2012;92:101–130. PubMed PMC

KATZ AM. Pathophysiology of heart failure: identifying targets for pharmacotherapy. Med Clin North Am. 2003;87:303–316. PubMed

KOPKAN L, HUSKOVÁ Z, SPORKOVÁ A, VARCABOVÁ Š , HONETSCHLAGEROVÁ Z, HWANG SH, TASI H-J, HAMMOCK BD, IMIG JD, KRAMER HJ, BURGELOVA M, VOJTÍŠKOVÁ A, KUJAL P, VERNEROVÁ Z, ČERVENKA L. Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney Blood Press Res. 2012;35:595–607. PubMed PMC

KUJAL P, ČERTÍKOVÁ CHÁBOVÁ V, ŠKAROUPKOVÁ P, HUSKOVÁ Z, VERNEROVÁ Z, KRAMER HJ, WALKOWSKA A, KOMPANOVSKA-JEZIERSKA E, SADOWSKI J, KITADA K, NISHIYAMA A, HWANG SH, HAMMOCK BD, IMIG JD, ČERVENKA L. Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Pharmacol Physiol. 2014;41:227–237. PubMed PMC

LEAR W, RUZICKA M, LEENEN FHH. ACE inhibitors and cardiac ACE mRNA in volume overload-induced cardiac hypertrophy. Am J Physiol. 1997;273:H641–H646. PubMed

LI N, LIU J-Y, TIMOFEYEV V, QIU H, HWANG SH, TUTEJA D, LU L, YANG J, MOCHIDA H, LOW R, HAMMOCK BD, CHIAMVIMONVAT N. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: insight gained using metabolomics approaches. J Mol Cell Cardiol. 2009;47:835–845. PubMed PMC

MELENOVSKY V, BENES J, SKAROUPKOVA P, SEDMERA D, STRNAD H, KOLAR M, VLCEK C, PETRAK J, BENES J, Jr., PAPOUSEK F, OLIYARNYK O, KAZDOVA L, CERVENKA L. Metabolic characterization of volume overload heart failure due to aorto-caval fistula in rats. Mol Cell Biochem. 2011;354:83–96. PubMed

MELENOVSKY V, SKAROUPKOVA P, BENES J, TORRESOVA V, KOPKAN L, CERVENKA L. The course of heart failure development and mortality in rats with volume overload due to aorto-caval fistula. Kidney Blood Press Res. 2012;35:167–173. PubMed

MERABET N, BELLIEN J, GLEVAREC E, NICOL L, LUCAS D, REMY-JOUET I, BOUNOURE F, DREANO Y, WECKER D, THUILEZ C, MULDER P. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure. J Mol Cell Cardiol. 2012;52:660–666. PubMed

MONTI J, FISCHER J, PASKA S, HEINING M, SCHULZ H, GOSELE C, HEUSER A, FISCHER R, SCHMIDT C, SCHIRDEWAN A, GROSS V, HUMMEL O, MAATZ H, PATONE G, SAAR K, VINGRON M, WELDON SM, LINDPAINTNER K, HAMMOCK BD, ROHDE K, DIETZ R, COOK SA, SCHUNCK W-H, LUFT FC, HUBNER N. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet. 2008;40:529–537. PubMed PMC

NECKÁŘ J, KOPKAN L, HUSKOVÁ Z, KOLÁŘ F, PAPOUŠEK F, KRAMER HJ, HWANG SH, HAMMOCK BD, IMIG JD, MALÝ J, NETUKA I, OŠŤÁDAL B, ČERVENKA L. Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-l-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive actions in transgenic rats with angiotensin II-dependent hypertension. Clin Sci. 2012;122:513–525. PubMed PMC

OLIVER-DUSSAULT C, ASCAH A, MARCIL M, MATAS J, PICARD S, PIBAROT P, BURELLE Y, DESCHEPPER CF. Early predictors of cardiac decompensation in experimental volume overload. Mol Cell Biochem. 2010;338:271–281. PubMed

OPIE LH, COMMERFORD PJ, GERSH BJ, PFEFFER MA. Controversies in ventricular remodeling. Lancet. 2006;367:356–367. PubMed

PACHER P, NAGAYAMA T, MUKHOPADHYAY P, BÁTKAI S, KASS DA. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc. 2008;3:1422–1434. PubMed PMC

PETRAK J, POSPISILOVA J, SEDINOVA M, JEDELSKY P, LORKOVA L, VIT O, KOLAR M, STRNAD H, BENES J, SEDMERA D, CERVENKA L, MELENOVSKY V. Proteomic and transcriptomic analysis of heart failure to volume overload in a rat aorto-caval fistula model provides support for new therapeutical targets – monoamine oxidase A and transglutaminase 2. Proteome Sci. 2011;9:69. http://www.proteomesci.com/content/9/1/69. PubMed PMC

PFEFFER JM, PFEFFER MA, MIRSKY I, BRAUNWALD E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Nat Acad Sic USA. 1982;79:3310–3314. PubMed PMC

PFEFFER MA, PFEFFER JM, STEINBERG C, FINN P. Survival after experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985;72:406–412. PubMed

PIERUZZI F, ABASSI ZA, KEISER HR. Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation. 1995;92:3105–3112. PubMed

ROGER VL. Epidemiology of heart failure. Circ Res. 2013;113:646–659. PubMed PMC

RONCO C, HAAPIO M, HOUSE AA, ANAVEKAR N, BELLOMO R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–1539. PubMed

RUZICKA M, YUAN B, HARMSEN E, LEENEN FHH. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats: effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation. 1993;87:921–930. PubMed

RYAN TD, ROTHSTEIN EC, ABAN I, TALLAJ JA, HUSAIN A, LUCCHESI PA, DELLÍTALIA LJ. Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload. J Am Coll Cardiol. 2007;49:811–821. PubMed

SCHROTEN NF, GAILLARD CA, van VELDHUISEN DJ, SZYMANSKI MK, HILLEGE HL, de BOER RA. New roles for renin and prorenin in heart failure and cardiorenal crosstalk. Heart Fail Rev. 2012;17:191–201. PubMed PMC

SPORKOVÁ A, KOPKAN L, VARCABOVÁ Š , HUSKOVÁ Z, HWANG SH, HAMMOCK BD, IMIG JD, KRAMER HJ, ČERVENKA L. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney, 1-clip hypertensive rats. Am J Physiol. 2011;300:R1468–R1475. PubMed PMC

YANG X-P, SABBAH HN, LIU Y-H, SHAROV VG, MASCHA EJ, ALWAN I, CARRETEO OA. Ventriculographic evaluation in three rat models of cardiac dysfunction. Am J Physiol. 1993;265:H1946–H1952. PubMed

WANG X, REN B, LIU S, SENTEX E, TAPPIA PS, DHALLA NS. Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. J Appl Physiol. 2003;94:752–763. PubMed

ZHANG K, WANG J, ZHANG H, CHEN J, ZOU J, ZOU Z, WANG J, HUANG H. Mechanisms of epoxyeicosatrienoic acids to improve cardiac remodeling in chronic renal failure disease. Eur J Pharmacol. 2013;701:33–39. PubMed

Effects of renal denervation on the course of cardiorenal syndrome: insight from studies with fawn-hooded hypertensive rats

Epoxylipids and soluble epoxide hydrolase in heart diseases

Effects of Trandolapril on Structural, Contractile and Electrophysiological Remodeling in Experimental Volume Overload Heart Failure

Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation

Deleterious Effects of Hyperactivity of the Renin-Angiotensin System and Hypertension on the Course of Chemotherapy-Induced Heart Failure after Doxorubicin Administration: A Study in Ren-2 Transgenic Rat

Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure

Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats

Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats

Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula